Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy

Rowan M. Thomson, Keith M. Furutani, Jose S Pulido, Scott L. Stafford, D. W O Rogers

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: Novel plaques are used to treat iris melanoma at the Mayo Clinic Rochester. The plaques are a modification of the Collaborative Ocular Melanoma Study (COMS) 22 mm plaque design with a gold alloy backing, outer lip, and silicone polymer insert. An inner lip surrounds a 10 mm diameter cutout region at the plaque center. Plaques span 360°, 270°, and 180° arcs. This article describes dosimetry for these plaques and others used in the treatment of anterior eye melanomas. Methods and Materials: The EGSnrc user-code BrachyDose is used to perform Monte Carlo simulations. Plaques and seeds are fully modeled. Three-dimensional dose distributions for different plaque models, TG-43 calculations, and 125I (model 6711) and 103Pd (model 200) seeds are compared via depth-dose curves, tabulation of doses at points of interest, and isodose contours. Results: Doses at points of interest differ by up to 70% from TG-43 calculations. The inner lip reduces corneal doses. Matching plaque arc length to tumor extent reduces doses to eye regions outside the treatment area. Maintaining the same prescription dose, 103Pd offers lower doses to critical structures than 125I, with the exception of the sclera adjacent to the plaque. Conclusion: The Mayo Clinic plaques offer several advantages for anterior eye tumor treatments. Doses to regions outside the treatment area are significantly reduced. Doses differ considerably from TG-43 predictions, illustrating the importance of complete Monte Carlo simulations. Calculations take a few minutes on a single CPU, making BrachyDose sufficiently fast for routine clinical treatment planning.

Original languageEnglish (US)
Pages (from-to)1261-1269
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume78
Issue number4
DOIs
StatePublished - Nov 4 2010

Fingerprint

Brachytherapy
Iris
Melanoma
Lip
dosage
Seeds
Gold Alloys
Sclera
Silicones
Therapeutics
Prescriptions
Neoplasms
Polymers
seeds
tumors
arcs
gold alloys
tabulation
backups
silicones

Keywords

  • BrachyDose
  • Dose calculation
  • EGSnrc
  • Eye plaque
  • Iris melanoma
  • Monte Carlo

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research
  • Medicine(all)

Cite this

Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy. / Thomson, Rowan M.; Furutani, Keith M.; Pulido, Jose S; Stafford, Scott L.; Rogers, D. W O.

In: International Journal of Radiation Oncology Biology Physics, Vol. 78, No. 4, 04.11.2010, p. 1261-1269.

Research output: Contribution to journalArticle

Thomson, Rowan M. ; Furutani, Keith M. ; Pulido, Jose S ; Stafford, Scott L. ; Rogers, D. W O. / Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy. In: International Journal of Radiation Oncology Biology Physics. 2010 ; Vol. 78, No. 4. pp. 1261-1269.
@article{1f5060494ad94889a6c89ffcc7ccd175,
title = "Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy",
abstract = "Purpose: Novel plaques are used to treat iris melanoma at the Mayo Clinic Rochester. The plaques are a modification of the Collaborative Ocular Melanoma Study (COMS) 22 mm plaque design with a gold alloy backing, outer lip, and silicone polymer insert. An inner lip surrounds a 10 mm diameter cutout region at the plaque center. Plaques span 360°, 270°, and 180° arcs. This article describes dosimetry for these plaques and others used in the treatment of anterior eye melanomas. Methods and Materials: The EGSnrc user-code BrachyDose is used to perform Monte Carlo simulations. Plaques and seeds are fully modeled. Three-dimensional dose distributions for different plaque models, TG-43 calculations, and 125I (model 6711) and 103Pd (model 200) seeds are compared via depth-dose curves, tabulation of doses at points of interest, and isodose contours. Results: Doses at points of interest differ by up to 70{\%} from TG-43 calculations. The inner lip reduces corneal doses. Matching plaque arc length to tumor extent reduces doses to eye regions outside the treatment area. Maintaining the same prescription dose, 103Pd offers lower doses to critical structures than 125I, with the exception of the sclera adjacent to the plaque. Conclusion: The Mayo Clinic plaques offer several advantages for anterior eye tumor treatments. Doses to regions outside the treatment area are significantly reduced. Doses differ considerably from TG-43 predictions, illustrating the importance of complete Monte Carlo simulations. Calculations take a few minutes on a single CPU, making BrachyDose sufficiently fast for routine clinical treatment planning.",
keywords = "BrachyDose, Dose calculation, EGSnrc, Eye plaque, Iris melanoma, Monte Carlo",
author = "Thomson, {Rowan M.} and Furutani, {Keith M.} and Pulido, {Jose S} and Stafford, {Scott L.} and Rogers, {D. W O}",
year = "2010",
month = "11",
day = "4",
doi = "10.1016/j.ijrobp.2009.12.002",
language = "English (US)",
volume = "78",
pages = "1261--1269",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Modified COMS plaques for 125I and 103Pd iris melanoma brachytherapy

AU - Thomson, Rowan M.

AU - Furutani, Keith M.

AU - Pulido, Jose S

AU - Stafford, Scott L.

AU - Rogers, D. W O

PY - 2010/11/4

Y1 - 2010/11/4

N2 - Purpose: Novel plaques are used to treat iris melanoma at the Mayo Clinic Rochester. The plaques are a modification of the Collaborative Ocular Melanoma Study (COMS) 22 mm plaque design with a gold alloy backing, outer lip, and silicone polymer insert. An inner lip surrounds a 10 mm diameter cutout region at the plaque center. Plaques span 360°, 270°, and 180° arcs. This article describes dosimetry for these plaques and others used in the treatment of anterior eye melanomas. Methods and Materials: The EGSnrc user-code BrachyDose is used to perform Monte Carlo simulations. Plaques and seeds are fully modeled. Three-dimensional dose distributions for different plaque models, TG-43 calculations, and 125I (model 6711) and 103Pd (model 200) seeds are compared via depth-dose curves, tabulation of doses at points of interest, and isodose contours. Results: Doses at points of interest differ by up to 70% from TG-43 calculations. The inner lip reduces corneal doses. Matching plaque arc length to tumor extent reduces doses to eye regions outside the treatment area. Maintaining the same prescription dose, 103Pd offers lower doses to critical structures than 125I, with the exception of the sclera adjacent to the plaque. Conclusion: The Mayo Clinic plaques offer several advantages for anterior eye tumor treatments. Doses to regions outside the treatment area are significantly reduced. Doses differ considerably from TG-43 predictions, illustrating the importance of complete Monte Carlo simulations. Calculations take a few minutes on a single CPU, making BrachyDose sufficiently fast for routine clinical treatment planning.

AB - Purpose: Novel plaques are used to treat iris melanoma at the Mayo Clinic Rochester. The plaques are a modification of the Collaborative Ocular Melanoma Study (COMS) 22 mm plaque design with a gold alloy backing, outer lip, and silicone polymer insert. An inner lip surrounds a 10 mm diameter cutout region at the plaque center. Plaques span 360°, 270°, and 180° arcs. This article describes dosimetry for these plaques and others used in the treatment of anterior eye melanomas. Methods and Materials: The EGSnrc user-code BrachyDose is used to perform Monte Carlo simulations. Plaques and seeds are fully modeled. Three-dimensional dose distributions for different plaque models, TG-43 calculations, and 125I (model 6711) and 103Pd (model 200) seeds are compared via depth-dose curves, tabulation of doses at points of interest, and isodose contours. Results: Doses at points of interest differ by up to 70% from TG-43 calculations. The inner lip reduces corneal doses. Matching plaque arc length to tumor extent reduces doses to eye regions outside the treatment area. Maintaining the same prescription dose, 103Pd offers lower doses to critical structures than 125I, with the exception of the sclera adjacent to the plaque. Conclusion: The Mayo Clinic plaques offer several advantages for anterior eye tumor treatments. Doses to regions outside the treatment area are significantly reduced. Doses differ considerably from TG-43 predictions, illustrating the importance of complete Monte Carlo simulations. Calculations take a few minutes on a single CPU, making BrachyDose sufficiently fast for routine clinical treatment planning.

KW - BrachyDose

KW - Dose calculation

KW - EGSnrc

KW - Eye plaque

KW - Iris melanoma

KW - Monte Carlo

UR - http://www.scopus.com/inward/record.url?scp=77958458327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958458327&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2009.12.002

DO - 10.1016/j.ijrobp.2009.12.002

M3 - Article

VL - 78

SP - 1261

EP - 1269

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -